Carcinoma, Renal Cell

Oncology·MeSH: Pancreatic Neoplasms

Prevalence

30.0 / 100K

11 drugs in development·4 companies·10 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
Belzutifan	Merck & Co., Inc. (MRK)
Zanzalintinib	Merck & Co., Inc. (MRK)

Phase 1(9)

Drug	Company
dff332	NOVARTIS AG (NVSEF)
dff332	Novartis AG (NVS)
gen-011	GENOCEA BIOSCIENCES, INC. (GNCA)
nir178	Novartis AG (NVS)
nir178	NOVARTIS AG (NVSEF)
pdr001	NOVARTIS AG (NVSEF)
pdr001	Novartis AG (NVS)
rad001	Novartis AG (NVS)
rad001	NOVARTIS AG (NVSEF)

BioSniper tracks 11 drugs in development for Carcinoma, Renal Cell across 4 companies.

There are 10 clinical trials targeting Carcinoma, Renal Cell tracked by BioSniper.

The estimated prevalence of Carcinoma, Renal Cell is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.